세계의 당뇨병 전증 시장 : 제품 유형별, 연령층별, 최종사용자별, 지역별, 기회 및 예측(2018-2032년)

Global prediabetes market is projected to witness a CAGR of 9.06% during the forecast period 2025-2032, growing from USD 330.54 million in 2024 to USD 661.29 million in 2032. Prediabetes cases are increasing due to rise of obesity, genetics factors, expansion of the aging population and increasing consumption of processed foods and sugar rich beverages. As per the estimate of the International Diabetes Federation, 853 million adults will have diabetes by 2050.

Increasing awareness among the general population and healthcare professionals about the importance of early detection of the condition and intervention to prevent the progression to type 2 diabetes is further propelling the market's demand. The rising population increases the demand of prediabetes-related products and services tremendously. Increasing obesity, unhealthy diet, and sedentary lifestyle are further increasing the risk of diabetes. Thus, leading market players are focusing on launching new products continuous glucose monitoring. For instance, in September 2024, Abbott Laboratories, launched Lingo, an over-the-counter (OTC) continuous glucose monitor (CGM) for adults that do not take insulin and want to improve their health.

Technological Advancement Supports Market Expansion

Technological advancements are driving the growth of the prediabetes market by enhancing diagnostic and monitoring capabilities, such as continuous glucose monitoring systems and digital health solutions. It also provides accurate and personalized treatment approaches by adding artificial intelligence (AI) and machine learning tools for quick results and provide relief for both patient and the healthcare provider. These innovations facilitate better management and awareness of prediabetes, addressing the rising incidence of lifestyle-related disease. Innovations in CGM systems, smartphone apps, portable glucometers and AI detection tools enhance the early detection of glucose irregularities and prevention from Type 2 diabetes. Almost half of all adults with diabetes are not aware that they are suffering from it, thus, leading players in the market are focusing on launching advanced diabetes detection tools. For instance, in November 2024, Redcliffe labs launched a digital diabetes risk checker tool on its official android app.

Increasing Research Activities Support Market Expansion

Ongoing clinical trials and research studies are expanding the understanding of prediabetes and allowing researchers to develop new therapies such as GLP-1 receptor agonists and combination therapies, which show promise in improving glycemic control and reducing associated risks. Research into biomarkers and advanced technologies like CGM are improving diagnostic precision and patient management. Various research institutions are focusing on developing programs that allow patients to reverse their prediabetes with lifestyle changes. For instance, in December 2024, a new program was launched in the St. John's region in Canada to assist individuals in reversing their progression toward type 2 diabetes. The four-week program is available across different YMCAs across Canada and is expected to aid patients in reversing their prediabetes with dietary changes and exercise.

Adults Hold Major Market Share

As per the age group adults have more diabetes due to the unhealthy lifestyle, obesity, genetics factors and lack of more consumption of fresh food products. As per the estimates of the International Diabetes Federation, in 2024, approximately 589 million adults were living with diabetes.

Individuals in this age group are more inclined to participate in regular health screenings, workplace wellness initiatives, and digital health monitoring, which contribute to the early identification and diagnosis of prediabetes. As healthcare professionals increasingly prioritize prevention and long-term health results, there is a heightened focus on early intervention, especially among younger individuals, to postpone or avert the development of type 2 diabetes. The rising use of fitness trackers, health applications, and telehealth services among adults aged 18-49 has also facilitated proactive health monitoring and lifestyle management, promoting early diagnosis and involvement in preventive healthcare.

North America Dominates the Prediabetes Market

North America is exerting its dominance in the prediabetes market due to a combination of high prevalence rates, advanced healthcare systems and effective public health strategies. In North America millions of adults are affected by prediabetes, creating significant demand for screening, diagnosis and treatment options. They enjoy robust healthcare infrastructures that facilitate early detection, preventive services, and insurance support. Initiatives such as the CDC's National Diabetes Prevention Programs (NDPP), along with considerable funding and public awareness efforts, further enhance market's expansion. Furthermore, North America is at the forefront of digital health innovation, evidenced by the extensive adoption of remote monitoring technologies, AI-powered applications, and interconnected devices deployed by companies such as Omada Health Inc. and Livongo (Teladoc Health, Inc.) are allowing for easy management of diabetes. Investment from the private sector in diabetes prevention and management technology also bolsters the region's prominence in this field.

Leading players in the reasons are focusing on launching new products and technology to reduce the burden of diabetes. For instance, March 2025 Tandem Diabetes Care, Inc. introduced its upgraded Control-IQ+ automated insulin delivery system in the United States.

Impact of U.S. Tariffs on Global Prediabetes Market

The tariffs imposed by the U.S. have introduced significant challenges for the prediabetes market and are expected to affect the accessibility and affordability of essential diagnostic and blood glucose monitoring tools that are essential in diabetes management. Additionally, tariffs are disrupting supply chains, leading to delays or shortages in the distribution of these products.

In response to the tariffs, leading pharmaceutical companies are investing in expanding their manufacturing base in the United States to reduce their reliance on imports. However, changes in manufacturing locations can trigger additional compliance requirements, resulting in delays in the introduction of new products and technologies.

Key Players Landscape and Outlook

Continuous innovation characterizes the landscape of prediabetes market globally, the market is driven by escalating prevalence of prediabetes and strong preference for preventive healthcare. To maintain their position in the market the key players are investing in innovation and research activities as well as nutraceuticals and functional foods. They collaborate with academic institutes and partner with pharmaceutical companies, tech firms and health care providers to integrate care modals.

For instance, in August 2024, Eli Lilly and Company announced favorable initial findings from the SURMOUNT-1 three-year trial assessing the effectiveness and safety of tirzepatide administered once a week for long-term weight management and delaying the onset of diabetes in adults with pre-diabetes and obesity or overweight.

Similarly, in March 2023, Pharma Linea Nutraceuticals Ltd launched Prediabetiq capsule to provide immediate improvements in glycemic response that can be easily measured in real-time.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of U.S. Tariffs

4. Executive Summary

5. Global Prediabetes Market Outlook, 2018-2032F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Product Type
    • 5.2.1.1. Diagnostics and Devices
      • 5.2.1.1.1. Blood Glucose Monitoring Devices
      • 5.2.1.1.2. Point-of-Care Testing (POCT) Devices
      • 5.2.1.1.3. Testing Kits
      • 5.2.1.1.4. Others
    • 5.2.1.2. Pharmaceuticals and Therapeutics
      • 5.2.1.2.1. Metformin and Oral Antidiabetics (OADs)
      • 5.2.1.2.2. Insulin Sensitizers
      • 5.2.1.2.3. Others
    • 5.2.1.3. Nutraceuticals and Functional Foods
      • 5.2.1.3.1. Blood Sugar Control Supplements
      • 5.2.1.3.2. Weight Management Supplements
      • 5.2.1.3.3. Others
    • 5.2.1.4. Others
  • 5.2.2. By Age Group
    • 5.2.2.1. Children
    • 5.2.2.2. Adults
    • 5.2.2.3. Elderly
  • 5.2.3. By End-user
    • 5.2.3.1. Hospitals and Clinics
    • 5.2.3.2. Diagnostic Centers
    • 5.2.3.3. Homecare Settings
    • 5.2.3.4. Others
  • 5.2.4. By Region
    • 5.2.4.1. North America
    • 5.2.4.2. Europe
    • 5.2.4.3. Asia-Pacific
    • 5.2.4.4. South America
    • 5.2.4.5. Middle East and Africa
  • 5.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 5.3. Market Map Analysis, 2024
  • 5.3.1. By Product Type
  • 5.3.2. By Age Group
  • 5.3.3. By End-user
  • 5.3.4. By Region

6. North America Prediabetes Market Outlook, 2018-2032F

• 6.1. Market Size Analysis & Forecast
  • 6.1.1. By Value
• 6.2. Market Share Analysis & Forecast
  • 6.2.1. By Product Type
    • 6.2.1.1. Diagnostics and Devices
      • 6.2.1.1.1. Blood Glucose Monitoring Devices
      • 6.2.1.1.2. Point-of-Care Testing (POCT) Devices
      • 6.2.1.1.3. Testing Kits
      • 6.2.1.1.4. Others
    • 6.2.1.2. Pharmaceuticals and Therapeutics
      • 6.2.1.2.1. Metformin and Oral Antidiabetics (OADs)
      • 6.2.1.2.2. Insulin Sensitizers
      • 6.2.1.2.3. Others
    • 6.2.1.3. Nutraceuticals and Functional Foods
      • 6.2.1.3.1. Blood Sugar Control Supplements
      • 6.2.1.3.2. Weight Management Supplements
      • 6.2.1.3.3. Others
    • 6.2.1.4. Others
  • 6.2.2. By Age Group
    • 6.2.2.1. Children
    • 6.2.2.2. Adults
    • 6.2.2.3. Elderly
  • 6.2.3. By End-user
    • 6.2.3.1. Hospitals and Clinics
    • 6.2.3.2. Diagnostic Centers
    • 6.2.3.3. Homecare Settings
    • 6.2.3.4. Others
  • 6.2.4. By Country Share
    • 6.2.4.1. United States
    • 6.2.4.2. Canada
    • 6.2.4.3. Mexico
• 6.3. Country Market Assessment
  • 6.3.1. United States Prediabetes Market Outlook, 2018-2032F*
    • 6.3.1.1. Market Size Analysis & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share Analysis & Forecast
  • 6.3.2. By Product Type
    • 6.3.2.1. Diagnostics & Devices
      • 6.3.2.1.1. Blood Glucose Monitoring Devices
      • 6.3.2.1.2. Point-of-Care Testing (POCT) Devices
      • 6.3.2.1.3. Testing Kits
      • 6.3.2.1.4. Others
    • 6.3.2.2. Pharmaceuticals and Therapeutics
      • 6.3.2.2.1. Metformin and Oral Antidiabetics (OADs)
      • 6.3.2.2.2. Insulin Sensitizers
      • 6.3.2.2.3. Others
    • 6.3.2.3. Nutraceuticals and Functional Foods
      • 6.3.2.3.1. Blood Sugar Control Supplements
      • 6.3.2.3.2. Weight Management Supplements
      • 6.3.2.3.3. Others
    • 6.3.2.4. Others
  • 6.3.3. By Age Group
    • 6.3.3.1. Children
    • 6.3.3.2. Adults
    • 6.3.3.3. Elderly
  • 6.3.4. By End-user
    • 6.3.4.1. Hospitals and Clinics
    • 6.3.4.2. Diagnostic Centers
    • 6.3.4.3. Homecare Settings
    • 6.3.4.4. Others
  • 6.3.5. Canada
  • 6.3.6. Mexico

All segments will be provided for all regions and countries covered

7. Europe Prediabetes Market Outlook, 2018-2032F

• 7.1. Germany
• 7.2. France
• 7.3. Italy
• 7.4. United Kingdom
• 7.5. Russia
• 7.6. Netherlands
• 7.7. Spain
• 7.8. Turkey
• 7.9. Poland

8. Asia-Pacific Prediabetes Market Outlook, 2018-2032F

• 8.1. India
• 8.2. China
• 8.3. Japan
• 8.4. Australia
• 8.5. Vietnam
• 8.6. South Korea
• 8.7. Indonesia
• 8.8. Philippines

9. South America Prediabetes Market Outlook, 2018-2032F

• 9.1. Brazil
• 9.2. Argentina

10. Middle East and Africa Prediabetes Market Outlook, 2018-2032F

• 10.1. Saudi Arabia
• 10.2. UAE
• 10.3. South Africa

11. Demand Supply Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

• 16.1. Market Drivers
• 16.2. Market Challenges

17. Market Trends and Developments

• 17.1. Product Launches and Approvals
• 17.2. Innovation
• 17.3. Clinical Trials

18. Policy and Regulatory Landscape

19. Case Studies

20. Competitive Landscape

• 20.1. Competition Matrix of Top 5 Market Leaders
• 20.2. SWOT Analysis for Top 5 Players
• 20.3. Key Players Landscape for Top 10 Market Players
  • 20.3.1. Abbott Laboratories
    • 20.3.1.1. Company Details
    • 20.3.1.2. Key Management Personnel
    • 20.3.1.3. Products and Services
    • 20.3.1.4. Financials (As Reported)
    • 20.3.1.5. Key Market Focus and Geographical Presence
    • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 20.3.2. F. Hoffmann-La Roche Ltd.
  • 20.3.3. Siemens Healthineers AG
  • 20.3.4. Ascensia Diabetes Care Holdings AG
  • 20.3.5. Omada Health, Inc.
  • 20.3.6. Noom, Inc.
  • 20.3.7. Eli Lilly and Company
  • 20.3.8. PharmaLinea nutraceuticals, Ltd.
  • 20.3.9. Oramed Pharmaceuticals Inc.
  • 20.3.10. Bayer AG

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer